AIM Immunotech Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AIM Immunotech Inc. on September 12, 2019. The report discloses a significant change in executive leadership, specifically the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance data.
Material Changes
- Executive Appointment: The Board of Directors unanimously appointed Ellen Lintal as the new Chief Financial Officer, effective September 15, 2019.
- Internal Promotion: Ms. Lintal was previously promoted to Chief Accounting Officer earlier in 2019 after joining the company in 2018 as Vice President of Finance & Control.
- Background: Ms. Lintal brings over 25 years of experience, including roles as CFO at an international non-profit and public company accounting experience at Corning Inc., Carlisle Companies, and AGY.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It notes that there are no family relationships between Ms. Lintal and the company's directors or officers, and no material transactions involving Ms. Lintal other than her employment.
Key Facts for Investor Verification
- Verify the effective date of Ellen Lintal's tenure as CFO (September 15, 2019).
- Review the press release dated September 16, 2019 (Exhibit 99.1) for additional details on the appointment.
- Confirm the absence of any undisclosed material transactions involving the new CFO.